FY2027 EPS Estimates for CG Oncology Increased by Analyst

CG Oncology, Inc. (NASDAQ:CGON) – Equities research analysts at HC Wainwright lifted their FY2027 earnings estimates for shares of CG Oncology in a research report issued to clients and investors on Tuesday, April 7th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($1.84) per share for the year, up from their previous forecast of ($1.90). HC Wainwright currently has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for CG Oncology’s FY2028 earnings at $0.06 EPS.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.10. The company had revenue of $2.32 million for the quarter.

A number of other research analysts have also recently commented on CGON. Morgan Stanley set a $93.00 price objective on CG Oncology in a report on Friday, January 9th. Wedbush initiated coverage on shares of CG Oncology in a research report on Thursday, December 11th. They set an “outperform” rating and a $70.00 price objective for the company. The Goldman Sachs Group reaffirmed a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a research report on Monday, January 12th. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Piper Sandler raised their price target on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research report on Friday, January 16th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, CG Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.67.

CG Oncology Trading Down 1.3%

CGON stock opened at $68.87 on Thursday. The company has a market cap of $5.81 billion, a price-to-earnings ratio of -33.27 and a beta of 0.70. CG Oncology has a 12 month low of $14.80 and a 12 month high of $71.90. The firm has a 50-day moving average of $60.03 and a two-hundred day moving average of $49.02.

Institutional Investors Weigh In On CG Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of CGON. Wellington Management Group LLP raised its stake in CG Oncology by 190.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock worth $222,055,000 after acquiring an additional 3,613,885 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in CG Oncology by 116.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock valued at $142,961,000 after purchasing an additional 1,854,386 shares during the period. Seven Fleet Capital Management LP acquired a new position in CG Oncology in the fourth quarter valued at $62,909,000. Bank of America Corp DE increased its stake in CG Oncology by 409.9% in the second quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock valued at $45,156,000 after purchasing an additional 1,396,170 shares during the period. Finally, State Street Corp increased its stake in CG Oncology by 46.4% in the fourth quarter. State Street Corp now owns 2,996,695 shares of the company’s stock valued at $124,423,000 after purchasing an additional 950,028 shares during the period. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director James Mulay sold 1,964 shares of CG Oncology stock in a transaction on Monday, March 16th. The shares were sold at an average price of $63.50, for a total transaction of $124,714.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 7.40% of the stock is owned by corporate insiders.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.